BioCentury | Jun 30, 2018
Regulation

Not a test

Antibiotics developers shouldn’t read too much into FDA’s rejection of the first drug to be reviewed under a new limited-use pathway that is supposed to make it easier to develop treatments for rare and resistant...
BioCentury | Apr 17, 2018
Distillery Therapeutics

Infectious disease

INDICATION: Bacterial infection; sepsis Cell culture and mouse studies identified an odilorhabdin-based bacterial ribosomal 30S subunit inhibitor that could help treat bacterial sepsis and other bacterial infections. Screening of small molecules derived from 80 strains...
BioCentury | Apr 9, 2018
Preclinical News

Nosopharm team identifies new class of antibiotics

Researchers at Nosopharm S.A.S. (Nimes, France) and academic colleagues identified a previously unknown class of naturally produced antibiotics that binds to a new site within the bacterial ribosome's decoding center and induces miscoding, killing the...
BioCentury | Feb 27, 2012
Clinical News

Aeroneb Go regulatory update

...for home use. The company plans to launch the products by the end of March. Aerogen...
BioCentury | Jan 24, 2011
Clinical News

Recipharm preclinical data

In mice, Recipharm's salmonella-based oral ORT-VAC DNA vaccine expressing the Myobacterium tuberculosis antigen MPT64 produced higher CD8+ immune responses compared to injected plasmid DNA, and also led to a reduction in pulmonary bacterial load following...
BioCentury | Jan 17, 2011
Company News

Aerogen, Dance Pharma Inc deal

...Aerogen and Dance partnered to develop Dance's inhaled insulin using Aerogen's OnQ aerosol technology. Under the...
...for developing and commercializing the product, while Aerogen is responsible for device modifications and manufacturing. Aerogen...
...undisclosed equity stake in Dance and is eligible for royalties. Further terms were not disclosed. Aerogen...
BioCentury | Aug 14, 2006
Company News

Biota, National Institutes of Health infectious news

...are partnered with Sankyo Co. Ltd. (Tokyo:4568; Osaka:4568, Tokyo, Japan) (see BioCentury, June 2, 2003). Aerogen Inc....
BioCentury | Aug 7, 2006
Company News

InterMune management update

...Musculoskeletal, Infectious, Pulmonary Hired: John Hodgman as SVP and CFO, formerly president and CEO of Aerogen Inc....
BioCentury | Feb 6, 2006
Strategy

Waiting to inhale

...filing could take place in late 2009. NKTR obtained the project from its acquisition of Aerogen Inc....
BioCentury | Jan 9, 2006
Company News

Codexis management update

...Hired: Robert Breuil as SVP and CFO, formerly CFO and VP of corporate development at Aerogen Inc. WIR...
Items per page:
1 - 10 of 103
BioCentury | Jun 30, 2018
Regulation

Not a test

Antibiotics developers shouldn’t read too much into FDA’s rejection of the first drug to be reviewed under a new limited-use pathway that is supposed to make it easier to develop treatments for rare and resistant...
BioCentury | Apr 17, 2018
Distillery Therapeutics

Infectious disease

INDICATION: Bacterial infection; sepsis Cell culture and mouse studies identified an odilorhabdin-based bacterial ribosomal 30S subunit inhibitor that could help treat bacterial sepsis and other bacterial infections. Screening of small molecules derived from 80 strains...
BioCentury | Apr 9, 2018
Preclinical News

Nosopharm team identifies new class of antibiotics

Researchers at Nosopharm S.A.S. (Nimes, France) and academic colleagues identified a previously unknown class of naturally produced antibiotics that binds to a new site within the bacterial ribosome's decoding center and induces miscoding, killing the...
BioCentury | Feb 27, 2012
Clinical News

Aeroneb Go regulatory update

...for home use. The company plans to launch the products by the end of March. Aerogen...
BioCentury | Jan 24, 2011
Clinical News

Recipharm preclinical data

In mice, Recipharm's salmonella-based oral ORT-VAC DNA vaccine expressing the Myobacterium tuberculosis antigen MPT64 produced higher CD8+ immune responses compared to injected plasmid DNA, and also led to a reduction in pulmonary bacterial load following...
BioCentury | Jan 17, 2011
Company News

Aerogen, Dance Pharma Inc deal

...Aerogen and Dance partnered to develop Dance's inhaled insulin using Aerogen's OnQ aerosol technology. Under the...
...for developing and commercializing the product, while Aerogen is responsible for device modifications and manufacturing. Aerogen...
...undisclosed equity stake in Dance and is eligible for royalties. Further terms were not disclosed. Aerogen...
BioCentury | Aug 14, 2006
Company News

Biota, National Institutes of Health infectious news

...are partnered with Sankyo Co. Ltd. (Tokyo:4568; Osaka:4568, Tokyo, Japan) (see BioCentury, June 2, 2003). Aerogen Inc....
BioCentury | Aug 7, 2006
Company News

InterMune management update

...Musculoskeletal, Infectious, Pulmonary Hired: John Hodgman as SVP and CFO, formerly president and CEO of Aerogen Inc....
BioCentury | Feb 6, 2006
Strategy

Waiting to inhale

...filing could take place in late 2009. NKTR obtained the project from its acquisition of Aerogen Inc....
BioCentury | Jan 9, 2006
Company News

Codexis management update

...Hired: Robert Breuil as SVP and CFO, formerly CFO and VP of corporate development at Aerogen Inc. WIR...
Items per page:
1 - 10 of 103